title: Neuroprotective activities of catalpol on MPP+/MPTP-induced neurotoxicity.
abstract: Catalpol is an iridoid glycoside, distributed in the roots of Rehmannia glutinosa Libosch. In vitro results showed that preincubation with catalpol (0.5-0.5 mM) for 0.5 hours before and during 48 hour exposure to 0.2 mM MPP+ appeared to be significant protective effect while catalopl was considerably less effective at the doses of 0.001 to 0.01 mM. The addition of catalpol at the dose of 0.05-0.5 mM significantly increased DA and DOPAC to MPP+ treated group. C57bl/6 mice received administration of catalpol for 12 hours before and during the 7 day treatment with MPTP. Such treatment at doses of 15 mg/kg significantly and dramatically blocked tyrosine hydroxylase-positive cell loss in mice. DA turnover in MPTP mice was reversed in the nigrostriatal pathway. In conclusion, data obtained in the above study suggested that catalpol exerted neuroprotective action in vitro and in vivo PD model.
authors.affiliation: School of Environmental and Biological Science and Technology, Dalian University of Technology, Dalian 116024, China. bojiang0411@yahoo.com.cn
authors.forename: Bo
authors.initials: B
authors.lastname: Jiang
authors.forename: Huang
authors.initials: H
authors.lastname: Zhang
authors.forename: Jing
authors.initials: J
authors.lastname: Bi
authors.forename: Xiu Li
authors.initials: XL
authors.lastname: Zhang
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005960:Glucosides / Q000627:therapeutic use*; D057888:Iridoid Glucosides; D039823:Iridoids / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D009498:Neurotoxins / Q000494:pharmacology*; D016716:PC12 Cells / Q000187:drug effects; D051381:Rats; D013778:Tetrazolium Salts; D013844:Thiazoles; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D005960:Glucosides; D057888:Iridoid Glucosides; D039823:Iridoids; D018696:Neuroprotective Agents; D009498:Neurotoxins; D013778:Tetrazolium Salts; D013844:Thiazoles; D015102:3,4-Dihydroxyphenylacetic Acid; C078040:catalpol; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; C022616:thiazolyl blue; D004298:Dopamine